Recent advances in pancreatology have significantly improved our understanding and management of pancreatic diseases.



This review summarizes key developments in basic research, epidemiology, diagnostics, and therapeutics in the field of pancreatology.

-Basic Research:

Recent studies have elucidated the molecular mechanisms underlying pancreatic diseases, such as pancreatitis and pancreatic cancer.

Researchers have identified new genes and signaling pathways involved in pancreatic cancer development, paving the way for targeted therapies.

Additionally, advances in organoid technology have allowed for the creation of three-dimensional models of the pancreas, enabling researchers to study disease mechanisms in more detail.


Epidemiological studies have provided insights into the risk factors for pancreatic diseases.

For example, studies have highlighted the role of smoking, obesity, and dietary factors in the development of pancreatic cancer.

These findings have informed public health efforts aimed at reducing the burden of pancreatic diseases.

Epidemiology and burden of pancreatic cancer


Advances in imaging techniques have improved the early detection and staging of pancreatic diseases.

For instance, endoscopic ultrasound (EUS) and magnetic resonance imaging (MRI) are now widely used for the evaluation of pancreatic lesions.

Furthermore, the identification of new biomarkers, such as circulating tumor DNA, has enhanced the accuracy of diagnosing pancreatic cancer.

MRI and EUS of gallstone pancreatitis, autoimmune pancreatitis Type 1 and Type 2 


Recent years have seen significant progress in the treatment of pancreatic diseases.

For pancreatic cancer, new chemotherapy regimens, targeted therapies, and immunotherapies have improved patient outcomes.

In addition, advances in surgical techniques, such as minimally invasive surgery, have reduced the morbidity associated with pancreatic surgery.

Moreover, the development of pancreatic enzyme replacement therapies has improved the quality of life for patients with pancreatic insufficiency.

The next wave of cellular immunotherapies in pancreatic cancer